PATH Act bill's introduction in Senate praised

The Infectious Disease Society of America (IDSA) welcomed the introduction of the Promise for Antibiotics and Therapeutics for Health (PATH) Act on Monday.

The bill aims for a smoother path to regulatory approval for compounds that treat infections from bacteria that are resistant to current forms of antibiotics. The bill was introduced by Sen. Michael Bennet (D-Colo.) and Sen. Orrin Hatch (R-Utah).

“Patients are dying from multi-drug-resistant infections, and we desperately need new antibiotics to save their lives. The PATH Act will create a feasible approval pathway that will allow these drugs to be brought to market,” IDSA President Dr. Steve Calderwood said.

Under current law no feasible way exists for developers to conduct traditional large-scale clinical trials due to the relatively small number of individuals who are infected with these sorts of diseases.

The IDSA stresses the need for research in this area before these infections begin to affect large groups of people.

The act also stipulates that drugs developed and approved under this pathway are clearly marked and that the use of the medication is monitored for resistance patterns. Also, all marketing materials must be approved.

“There is clear agreement among medical, scientific and public health leaders that the federal government must act to stimulate development of urgently needed new antibiotics. There is broad support for the limited-population antibacterial drug pathway which the PATH Act would establish. Congress must continue the momentum driving this issue on behalf of patients. IDSA looks forward to working with Senators Bennet and Hatch to enact the PATH Act,” Calderwood said.

Organizations in this Story

Infectious Diseases Society of America

Want to get notified whenever we write about Infectious Diseases Society of America ?
Next time we write about Infectious Diseases Society of America, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.